Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma (SPL) signs a deal for its antiviral nasal spray to be available for purchase across nine new countries
- Through a five-year sales and distribution agreement, VIRALEZE will be available for purchase in Saudi Arabia and eight other countries, including the United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain
- Meanwhile, Starpharma has been negotiating an arrangement for the sales and distribution of its antiviral product to other neighbouring countries
- VIRALEZE is now registered in more than 30 countries, including Europe, Vietnam, India, New Zealand, and Saudi Arabia, and available online in certain markets
- Starpharma is down 1.41 per cent to $1.05
Starpharma (SPL) has signed a distribution agreement for its antiviral nasal spray across nine new countries.
Through an exclusive sales and distribution agreement, VIRALEZE will be available for purchase in Saudi Arabia and eight other countries, including the United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain.
VIRALEZE is a broad-spectrum antiviral nasal spray that has been proven to have potent antiviral activity in multiple respiratory viruses, including influenza and multiple variants of SARS-CoV-2.
The five-year deal was penned with Etqan & Nazahah LLC (E&N), an agent and distributor of medical and pharmaceutical products, headquartered in Saudi Arabia.
Starpharma will supply VIRALEZE, with E&N then responsible for sales, distribution, and marketing of the product. Under the deal, VIRALEZE will be available to retail consumers, clinics, hospitals, pharmacies and online.
VIRALEZE is registered for sale in Saudi Arabia, with the registration expected to facilitate further registrations across the region.
“We are very pleased to partner with E&N for the sale and distribution of VIRALEZE in Saudi Arabia and the wider GCC region, and to continue building on the brand presence of VIRALEZE internationally,” said Dr Jackie Fairley, Starpharma CEO.
Meanwhile, Starpharma has been negotiating an arrangement for the sales and distribution of its antiviral product to other neighbouring countries.
VIRALEZE is now registered in more than 30 countries, including Europe, Vietnam, India, New Zealand, and Saudi Arabia, and available online in certain markets.
Starpharma was down 1.41 per cent to $1.05 at 10:40 am AEDT.
